Predictive model for sarcopenia in patients with non-small cell lung cancer and malignant pleural effusion

被引:0
|
作者
Gao, Hengxing [1 ,2 ]
Zou, Xuexue [3 ]
Fan, Meng [1 ]
Chen, Mingwei [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, 277 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 1, Medx Inst, Xian 710061, Shaanxi, Peoples R China
[3] Binzhou Med Univ Hosp, Dept Radiol, 661 Yellow River Rd, Binzhou 256600, Shandong, Peoples R China
关键词
Sarcopenia; Non-small cell lung cancer; Malignant pleural effusion; Predictive indicators; Nomogram; OUTCOMES; RISK;
D O I
10.1186/s12885-025-13772-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundSarcopenia in patients with non-small cell lung cancer (NSCLC) is often indicative of a more aggressive disease course and a poorer prognosis. Nevertheless, there have been limited studies that specifically examined clinical parameters to predict sarcopenia in individuals with malignant pleural effusion (MPE). Our objective is to investigate the potential correlations between commonly utilized clinical variables and reduced muscle mass in NSCLC patients who also have MPE.MethodsThis retrospective study examined the clinicopathological data and imaging characteristics of NSCLC patients admitted to the hospital with MPE. The Least Absolute Shrinkage and Selection Operator (LASSO) algorithm was employed to select the most appropriate variables for model creation, effectively reducing the chance of overfitting. Logistic regression analysis was conducted to pinpoint the independent factors predicting sarcopenia in NSCLC patients with MPE. Subsequently, a nomogram was formulated to estimate the sarcopenia risk for individual patient. The efficacy of this nomogram was assessed through various metrics, including the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA).ResultsA total of 139 patients, with an average age of 66 years and a majority being male (56.8%), were included in this study. Multivariate logistic regression analysis revealed that age, body mass index (BMI), albumin (Alb), and cytokeratin-19-fragment (CY21-1) were all independent predictors of sarcopenia in NSCLC patients with MPE. A nomogram was developed to facilitate personalized prediction of sarcopenia for individual patient. The ROC curve demonstrated that the nomogram model incorporating these predictive factors achieved an area under the curve (AUC) of 0.889, indicating its discriminatory power in predicting sarcopenia. The calibration curve demonstrated a strong concordance between the actual and the anticipated sarcopenia risk. DCA further confirmed that the nomogram showed good clinical applicability and net benefits in sarcopenia prediction.ConclusionsCertain commonly used clinical characteristics were found to be associated with decreased skeletal muscle mass. Specifically, age, BMI, Alb, and CY21-1 levels emerged as predictive indicators for sarcopenia among NSCLC patients with MPE. These indicators have the potential to serve as effective alternatives to traditional computed tomography (CT) evaluation in assessing sarcopenia.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Development a predictive nomogram for spontaneous pleurodesis in patients with non-small cell lung cancer and malignant pleural effusion
    Tan, Sihan
    Zeng, Hao
    Huang, Qin
    Pu, Xin
    Li, Weimin
    Ali, Jason M.
    Nayak, Rahul
    Bhagat, Milind
    Li, Yalun
    Tian, Panwen
    JOURNAL OF THORACIC DISEASE, 2025, 17 (02)
  • [2] Does the Amount of Malignant Pleural Effusion Affect the Survival in Patients with Non-Small Cell Lung Cancer?
    Nakamura, Shota
    Okasaka, Toshiki
    Kawaguchi, Koji
    Fukui, Takayuki
    Fukumoto, Koichi
    Yokoi, Kohei
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S727 - S727
  • [3] MOLECULAR TESTING AND CYTOPATHOLOGIC FEATURES OF MALIGNANT PLEURAL EFFUSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Fujii, T.
    Fukawa, T.
    Kishi, K.
    Ohashi, K.
    ACTA CYTOLOGICA, 2010, 54 (03) : 414 - 414
  • [4] The therapeutic efficacy of osimertinib in non-small cell lung cancer with malignant pleural effusion
    Nagamine, Hiroaki
    Sawa, Kenji
    Kaneda, Hiroyasu
    Ogawa, Koichi
    Nakahama, Kenji
    Matsumoto, Yoshiya
    Tani, Yoko
    Mitsuoka, Shigeki
    Kimura, Tatsuo
    Kawaguchi, Tomoya
    ANNALS OF ONCOLOGY, 2022, 33 : S523 - S523
  • [5] The prognostic significance of malignant pleural effusion at the time of thoracotomy in patients with non-small cell lung cancer
    Fukuse, T
    Hirata, T
    Tanaka, F
    Wada, H
    LUNG CANCER, 2001, 34 (01) : 75 - 81
  • [6] The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer
    Chen, Yao
    Mathy, Nicholas W.
    Lu, Hongda
    MOLECULAR MEDICINE REPORTS, 2018, 17 (06) : 8019 - 8030
  • [7] Prognostic value of pleural effusion in patients with non-small cell lung cancer
    Sugiura, S
    Ando, Y
    Minami, H
    Ando, M
    Sakai, S
    Shimokata, K
    CLINICAL CANCER RESEARCH, 1997, 3 (01) : 47 - 50
  • [8] Predictive Value of F-18 FDG PET/CT for Malignant Pleural Effusion in Non-Small Cell Lung Cancer Patients
    Kim, Bum Soo
    Kim, In Joo
    Kim, Seong-Jang
    Pak, Kyoungjune
    Kim, Keunyoung
    ONKOLOGIE, 2011, 34 (06): : 298 - 303
  • [9] EFFICACY AND SAFETY OF CHEMOTHERAPY CONTAINING BEVACIZUMAB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH MALIGNANT PLEURAL EFFUSION
    Fujii, Mitsuhiro
    Iwakami, Shin-Ichiro
    Ihara, Hiroaki
    Hara, Munechika
    Iwakami, Naoko
    Ishiwata, Toshiji
    Takahashi, Kazuhisa
    RESPIROLOGY, 2013, 18 : 87 - 87
  • [10] Molecular profile of malignant pleural effusion (MPE) in non-small cell lung cancer (NSCLC)
    Rodriguez, Irene Lojo
    Rial, Maribel Botana
    Montaos, Almudena Gonzalez
    Pineiro, Ana Gonzalez
    Hernandez, Cristina Ramos
    Delgado, Mercedes Cuna
    Delgado, Manuel Nunez
    Villar, Alberto Fernandez
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64